Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Authors' conclusion
Linezolid body clearance in ACLF was markedly lower than in NLF.
Study context
- Population
- Critically ill patients on continuous renal replacement therapy receiving linezolid 600 mg bid
- Participants
- 18 patients
- Exposure
- Acute-on-chronic liver failure (ACLF) vs NLF
- ACLFn = 9
- Outcome
- Linezolid body clearance
Methodological detailspopulation pharmacokinetic modelling, Monte-Carlo simulations
- Population pharmacokinetic modelling
- Monte-Carlo simulations
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Trough concentration target attainment 2-7 mg/L with 600 mg bid (simulation)
Underexposed
Overexposed
Highest probability of target exposure (simulation)
- Attained with 600 mg bid in NLF and 150 mg bid in ACLF
- 53%
Original publication
Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study. Ann Intensive Care. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →